Fresenius

• 

  Nestle Poaches CEO From Fresenius In Health And Wellness Drive

  Nestle SA named Ulf Mark Schneider as its next chief executive in a surprise choice on Monday, as the Swiss food giant underlined a shift towards health and wellness by poaching the boss of German healthcare group Fresenius.

• 

  Claris Settles Litigation with Fresenius Kabi on 'Diprivan'

  In December 2014, Fresenius Kabi had filed a suit against Claris Lifesciences to block commercialisation of its abbreviated new drug application (ANDA) for Propofol, used to induce or maintain anesthesia during surgeries.

• Fresenius Kabi plunges 19% ahead of SAT hearing on delisting

  At the NSE, the stock tumbled 18.64 per cent to Rs 119.10. Fresenius Kabi Oncology has again approached SAT against Sebi which recently gave a conditional nod to the company to delist from the Indian stock market.

• US FDA asks Indian drugmakers to comply or face action

  The US Food and Drug Administration (FDA) also warned of "appropriate action" against the companies who fail to implement "Good Manufacturing Practices".

• Tribunal to hear Fresenius Kabi appeal against Sebi on Jun 24

  The Securities Appellate Tribunal (SAT) will hear on June 24 healthcare firm Fresenius Kabi Oncology's appeal against an order by the Securities and Exchange Board of India (Sebi) related to non-compliance with 25 per cent minimum public shareholding norms.

• Fresenius Kabi challenges Sebi's minimum public holding order

  Healthcare firm Fresenius Kabi Oncology approached the Securities Appellate Tribunal (SAT) on Wednesday against market regulator Securities and Exchange Board of Indias order on minimum 25 per cent public shareholding and sought permission to delist its shares from the stock exchanges.

• Parenteral Drugs to sell unit to Fresenius Kabi India for Rs 200 crore

  Parenteral Drugs on Friday said its subsidiary, Goa Formulations, has entered into an agreement with Fresenius Kabi India to sell its pharmaceutical manufacturing unit at Goa for Rs 200 crore.

• Action-packed weeks ahead for shares of multinational companies: Analysts

  Shares of multi-national companies (MNCs) will be in focus in the next few weeks as many of them will be required to either reduce promoter shareholding to a regulatory cap of 75 per cent or get delisted.

• Fresenius Kabi Oncology Ltd - Disinvestment of entire shareholding in subsidiary company

  With reference to earlier announcement dated May 27, 2011 regarding disinvestment of Fresenius Kabi Oncology Ltd's entire shareholding in Fresenius Kabi Oncology Plc, UK to Fresenius Kabi, Germany and its affiliates, Fresenius Kabi Oncology Ltd has now informed BSE that the Company has finalized and executed the share purchase agreement with Fr...

• Fresenius Kabi Oncology Ltd - Fixes Book Closure for AGM

  Fresenius Kabi Oncology Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 01, 2011 to August 11, 2011 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on August 11, 2011.

• Fresenius Kabi Oncology Ltd - Outcome of Board Meeting

  Fresenius Kabi Oncology Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2011, inter alia, has: 1. Not recommended any dividend for the year. 2. Recommended the re-appointment of Dr. Michael Schonhofen as a Director liable to retire by rotation. 3. Recommended the re-appointment of Mr. Nitin Potdar as a...

• MNCs soar as new public holding norm triggers delisting hope

  Companies with foreign promoter holding above 75% spurted. BOC India (up 11.12%), 3M India (up 8.51%), Oracle Financial Services (up 6.62%), Atlas Copco (India) (up 5.91%), Alfa Laval (India) (up 5.89%), Novartis India (up 5.03%), Fresenius Kabi Oncology (up 5.01%), Honeywell Automation (up 4.42%), Sulzer India (up 3.32%), rose. Companies with ...

• Fresenius Kabi Oncology reports net profit of Rs 80.23 crore in the year ended March 2010

  Sales rise 59.80% to Rs 412.20 croreFresenius Kabi Oncology reported net profit of Rs 80.23 crore in the year ended March 2010 as against net loss of Rs 77.69 crore during the previous year ended March 2009. Sales rose 59.80% to Rs 412.20 crore in the year ended March 2010 as against Rs 257.94 crore during the previous year ended March 2009.

• Fresenius Kabi enters into a license & settlement agreement with Sanofi-Aventis

  Fresenius Kabi Oncology has announced that it has entered into a license and settlement agreement with Sanofi-Aventis, covering patents that apply to Eloxatin (Oxaliplatin Injection and Oxaliplatin for injection). The agreement with Sanofi-Aventis resolves a patent infringement lawsuit, which was pending in the United States District Court for the ...

• Fresenius Kabi Oncology appoints director

  With effect from 20 January 2010 The board of Fresenius Kabi Oncology in its meeting on 20 January 2010 has appointed Mats Christer Henriksson as director of the company with effect from 20 January 2010.